Skip to Content

Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

About this PQI

Tepotinib is an oral tyrosine kinase inhibitor (TKI) designed specifically to target mesenchymal epithelial transition exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC).1 This PQI will discuss safety, efficacy, strategies for dosing, and side effect management.

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI